Altimmune sees phase 1 success in tricky NASH indication with GLP-1 agonist

Altimmune’s phase 1b study evaluating its obesity and non-alcoholic steatohepatitis (NASH) treatment has hit its main target, along with a secondary goal. It makes for some welcome topline data in a notoriously tricky indication.